Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Bladder Cancer

Free Subscription 02.10.2023 1 ACS Appl Mater Interfaces 1 ACS Nano 1 Adv Sci (Weinh) 1 Ann Surg Oncol 1 Biochemistry (Mosc) 1 BMC Urol 1 Cancer Cell Int 1 Cancer Res 1 Cancers (Basel) 1 Cell Mol Life Sci 1 Cell Signal 1 Chem Biol Interact 1 Clin Genitourin Cancer 1 Cureus 1 Curr Oncol 1 Diagn Pathol 1 Dokl Biochem Biophys 1 Expert Rev Anticancer Ther 2 Int J Mol Sci 2 Int J Urol 1 Int Urol Nephrol 1 J Cancer Res Clin Oncol 1 J Clin Med 2 J Pers Med 1 J Transl Med 4 J Urol 1 JAMA Oncol 1 Mol Biotechnol 1 Pharmacol Res 1 Public Health 1 Scand J Urol 1 Sci Rep 2 Urology 1 Vasc Endovascular Surg

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

ACS Appl Mater Interfaces

1. QIU H, Wang J, Zhi Y, Yan B, et al
   Hyaluronic Acid-Conjugated Fluorescent Probe-Shielded Polydopamine Nanomedicines for Targeted Imaging and Chemotherapy of Bladder Cancer.
   ACS Appl Mater Interfaces. 2023 Sep 28. doi: 10.1021/acsami.3c09564.
   PubMed         Abstract available
   
   

   
   ACS Nano

2. ZHANG W, Cai K, Sun Z, Xiang Q, et al
   Elevating Second Near-Infrared Photothermal Conversion Efficiency of Hollow Gold Nanorod for a Precise Theranostic of Orthotopic Bladder Cancer.
   ACS Nano. 2023 Sep 28. doi: 10.1021/acsnano.3c04175.
   PubMed         Abstract available
   
   

   
   Adv Sci (Weinh)

3. LIANG T, Tao T, Wu K, Liu L, et al
   Cancer-Associated Fibroblast-Induced Remodeling of Tumor Microenvironment in Recurrent Bladder Cancer.
   Adv Sci (Weinh). 2023 Sep 24:e2303230. doi: 10.1002/advs.202303230.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

4. SLUSARCZYK A, Zapala P
   Reply to Letter to Editor: Cancer-Specific Mortality of Non-Muscle-Invasive Bladder Cancer.
   Ann Surg Oncol. 2023 Sep 27. doi: 10.1245/s10434-023-14360.
   PubMed        
   
   

   
   Biochemistry (Mosc)

5. SACHKO AM, Goryainova OS, Ivanova TI, Nikolaeva IY, et al
   Analysis of Transferrin in the Urine of Patients with Bladder Cancer Using Nanobodies.
   Biochemistry (Mosc). 2023;88:1105-1115.
   PubMed         Abstract available
   
   

   
   BMC Urol

6. JIANG R, Wang X, Li Z, Cai H, et al
   Association of metabolic syndrome and its components with the risk of urologic cancers: a prospective cohort study.
   BMC Urol. 2023;23:150.
   PubMed         Abstract available
   
   

   
   Cancer Cell Int

7. ZOU F, Chen W, Song T, Xing J, et al
   SQLE Knockdown inhibits bladder cancer progression by regulating the PTEN/AKT/GSK3beta signaling pathway through P53.
   Cancer Cell Int. 2023;23:221.
   PubMed         Abstract available
   
   

   
   Cancer Res

8. OUYANG Y, Ou Z, Zhong W, Yang J, et al
   FGFR3 alterations in bladder cancer stimulate serine synthesis to induce immune-inert macrophages that suppress T-cell recruitment and activation.
   Cancer Res. 2023 Sep 28. doi: 10.1158/0008-5472.CAN-23-1065.
   PubMed         Abstract available
   
   

   
   Cancers (Basel)

9. KHORAMINIA F, Fuster S, Kanwal N, Olislagers M, et al
   Artificial Intelligence in Digital Pathology for Bladder Cancer: Hype or Hope? A Systematic Review.
   Cancers (Basel). 2023;15:4518.
   PubMed         Abstract available
   
   

   
   Cell Mol Life Sci

10. WANG X, Liu J, Azoitei A, Eiseler T, et al
    Loss of ORP3 induces aneuploidy and promotes bladder cancer cell invasion through deregulated microtubule and actin dynamics.
    Cell Mol Life Sci. 2023;80:299.
    PubMed         Abstract available
    
    

    
    Cell Signal

11. ZOU F, Rao T, Chen W, Song T, et al
    DUSP2 affects bladder cancer prognosis by down-regulating MEK/ERK and P38 MAPK signaling pathways through PTPN7.
    Cell Signal. 2023;112:110893.
    PubMed         Abstract available
    
    

    
    Chem Biol Interact

12. WANG L, Song R, Ma M, Chen Y, et al
    Inhibition of autophagy can promote the apoptosis of bladder cancer cells induced by SC66 through the endoplasmic reticulum stress pathway.
    Chem Biol Interact. 2023 Sep 21:110725. doi: 10.1016/j.cbi.2023.110725.
    PubMed         Abstract available
    
    

    
    Clin Genitourin Cancer

13. ELKARTA A, Awadalla A, El-Hefnawy A, Mosbah A, et al
    Predictors of Response Following Neoadjuvant Cisplatin-Based Chemotherapy for Muscle Invasive Urothelial Bladder Cancer Using Molecular Profile: A Prospective Clinical Study.
    Clin Genitourin Cancer. 2023 Aug 10:S1558-7673(23)00186.
    PubMed         Abstract available
    
    

    
    Cureus

14. MAGALHAES JC, Sousa M, Basto R, Fraga T, et al
    Adjuvant Hyperthermic Intravesical Chemotherapy in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer.
    Cureus. 2023;15:e45672.
    PubMed         Abstract available
    
    

    
    Curr Oncol

15. SABATE ORTEGA J, Fort Culillas R, Escoda Garcia M, Vasquez-Dongo CA, et al
    Case Report: A Presentation of Early-Onset Immune-Mediated Bullous Pemphigoid in a Patient with Urothelial Cancer.
    Curr Oncol. 2023;30:7802-7809.
    PubMed         Abstract available
    
    

    
    Diagn Pathol

16. KOBAYASHI G, Hayashi T, Sentani K, Uraoka N, et al
    MCM4 expression is associated with high-grade histology, tumor progression and poor prognosis in urothelial carcinoma.
    Diagn Pathol. 2023;18:106.
    PubMed         Abstract available
    
    

    
    Dokl Biochem Biophys

17. YANOVA MR, Zhiyanov AP, Antipenko ID, Slobodov SA, et al
    Intracellular Gemcitabine Monophosphate Levels Predict Chemotherapy Efficacy in Gemcitabine-Treated Patients with Bladder Cancer.
    Dokl Biochem Biophys. 2023 Sep 29. doi: 10.1134/S1607672923700503.
    PubMed         Abstract available
    
    

    
    Expert Rev Anticancer Ther

18. KOGA F
    Selective multimodal bladder-sparing therapy for muscle-invasive bladder cancer: the present and the future.
    Expert Rev Anticancer Ther. 2023 Sep 27:1-13. doi: 10.1080/14737140.2023.2257389
    PubMed         Abstract available
    
    

    
    Int J Mol Sci

19. ELAHI NAJAFI MA, Yasui M, Teramoto Y, Tatenuma T, et al
    GABBR2 as a Downstream Effector of the Androgen Receptor Induces Cisplatin Resistance in Bladder Cancer.
    Int J Mol Sci. 2023;24:13733.
    PubMed         Abstract available
    
    
20. FLORES MONAR GV, Reynolds T, Gordon M, Moon D, et al
    Molecular Markers for Bladder Cancer Screening: An Insight into Bladder Cancer and FDA-Approved Biomarkers.
    Int J Mol Sci. 2023;24:14374.
    PubMed         Abstract available
    
    

    
    Int J Urol

21. FUKUSHIMA H
    Editorial Comment to Impact on Japanese healthcare economics of photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer: A multicenter retrospective cohort study.
    Int J Urol. 2023 Sep 22. doi: 10.1111/iju.15308.
    PubMed        
    
    
22. KIKUCHI E, Hayakawa N
    Editorial Comment to "Improving compliance with guidelines may lead to favorable clinical outcomes for patients with non-muscle-invasive bladder cancer: A retrospective multicenter study".
    Int J Urol. 2023 Sep 27. doi: 10.1111/iju.15311.
    PubMed        
    
    

    
    Int Urol Nephrol

23. XIAOQIN Z, Zhouqi L, Huan P, Xinyi F, et al
    Development of a prognostic signature for immune-associated genes in bladder cancer and exploring potential drug findings.
    Int Urol Nephrol. 2023 Sep 23. doi: 10.1007/s11255-023-03796.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

24. LIU J, Wu P, Lai S, Wang J, et al
    Identifying possible hub genes and biological mechanisms shared between bladder cancer and inflammatory bowel disease using machine learning and integrated bioinformatics.
    J Cancer Res Clin Oncol. 2023 Sep 23. doi: 10.1007/s00432-023-05266.
    PubMed         Abstract available
    
    

    
    J Clin Med

25. YE L, Wang Y, Xiang W, Yao J, et al
    Radiomic Analysis of Quantitative T2 Mapping and Conventional MRI in Predicting Histologic Grade of Bladder Cancer.
    J Clin Med. 2023;12:5900.
    PubMed         Abstract available
    
    

    
    J Pers Med

26. SCHULZ HAGERSTEN E, Ottosson K, Pelander S, Johansson M, et al
    The Risk of Thromboembolism in Patients with Muscle Invasive Bladder Cancer before and after Cystectomy Depending on Blood Group and Neoadjuvant Chemotherapy-A Multicentre Retrospective Cohort Study.
    J Pers Med. 2023;13:1355.
    PubMed         Abstract available
    
    
27. PETEINARIS A, Perros P, Prokopakis I, Fasoulakis Z, et al
    Bladder Cancer during Pregnancy: A Review of the Literature.
    J Pers Med. 2023;13:1418.
    PubMed         Abstract available
    
    

    
    J Transl Med

28. LIU T, Fan MQ, Xie XX, Shu QP, et al
    Activation of CTNNB1 by deubiquitinase UCHL3-mediated stabilization facilitates bladder cancer progression.
    J Transl Med. 2023;21:656.
    PubMed         Abstract available
    
    

    
    J Urol

29. PRASAD SM
    Primary Chemoablation for Intermediate-Risk Low-Grade Bladder Cancer: New Paradigm or Added Uncertainty? Letter.
    J Urol. 2023 Sep 28:101097JU0000000000003729. doi: 10.1097/JU.0000000000003729.
    PubMed        
    
    
30. MURTHY PB, Sexton WJ
    Primary Chemoablation for Intermediate-risk Low-grade Bladder Cancer: New Paradigm or Added Uncertainty?
    J Urol. 2023 Sep 27:101097JU0000000000003702. doi: 10.1097/JU.0000000000003702.
    PubMed        
    
    
31. BREE KK, Navai N
    Repeat Transurethral Resection of Muscle-Invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Reply.
    J Urol. 2023 Sep 25:101097JU0000000000003704. doi: 10.1097/JU.0000000000003704.
    PubMed        
    
    
32. BREE K, Navai N
    Repeat Transurethral Resection of Muscle-Invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Reply.
    J Urol. 2023 Sep 25:101097JU0000000000003705. doi: 10.1097/JU.0000000000003705.
    PubMed        
    
    

    
    JAMA Oncol

33. SPAAS M, Sundahl N, Kruse V, Rottey S, et al
    Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial.
    JAMA Oncol. 2023;9:1205-1213.
    PubMed         Abstract available
    
    

    
    Mol Biotechnol

34. ZHENG K, Li M
    Predicting Survival Signature of Bladder Cancer Related to Cancer-Associated Fibroblast (CAF) Constructed by Intersecting Genes in TCGA and GEO.
    Mol Biotechnol. 2023 Sep 25. doi: 10.1007/s12033-023-00892.
    PubMed         Abstract available
    
    

    
    Pharmacol Res

35. TAN M, Pan Q, Gong H, Zhai X, et al
    Super-enhancer-associated SNHG15 cooperating with FOSL1 contributes to bladder cancer progression through the WNT pathway.
    Pharmacol Res. 2023 Sep 25:106940. doi: 10.1016/j.phrs.2023.106940.
    PubMed         Abstract available
    
    

    
    Public Health

36. LI W, Li C, Liu T, Wang Y, et al
    Self-reported sleep disorders and the risk of all cancer types: evidence from the Kailuan Cohort study.
    Public Health. 2023;223:209-216.
    PubMed         Abstract available
    
    

    
    Scand J Urol

37. LIND AK, Liedberg F, Aljabery F, Blackberg M, et al
    Health-related quality of life prior to and 1 year after radical cystectomy evaluated with FACT-G and FACT-VCI questionnaires.
    Scand J Urol. 2023;58:76-83.
    PubMed         Abstract available
    
    

    
    Sci Rep

38. ZHAN Y, Liu Y, Lin J, Fu X, et al
    Author Correction: Synthetic Tet-inducible artificial microRNAs targeting beta-catenin or HIF-1alpha inhibit malignant phenotypes of bladder cancer cells T24 and 5637.
    Sci Rep. 2023;13:16331.
    PubMed        
    
    

    
    Urology

39. HYLLESTED E, Vejlgaard M, Stroomberg HV, Maibom SL, et al
    Acute Kidney Injury within 90 days of Radical Cystectomy for Bladder Cancer: Incidence and Risk Factors.
    Urology. 2023 Sep 22:S0090-4295(23)00807-5. doi: 10.1016/j.urology.2023.
    PubMed         Abstract available
    
    
40. VEJLGAARD M, Maibom SL, Joensen UN, Moser C, et al
    Microbial trends in infection-related readmissions following radical cystectomy for bladder cancer.
    Urology. 2023 Sep 22:S0090-4295(23)00805-1. doi: 10.1016/j.urology.2023.
    PubMed         Abstract available
    
    

    
    Vasc Endovascular Surg

41. GODARD L, Lee L, McGuinness B, Shirsat H, et al
    Mycotic Abdominal Aortic Aneurysm Secondary to BCG Therapy for Non-muscle Invasive Urothelial Carcinoma of the Bladder.
    Vasc Endovascular Surg. 2023;57:776-780.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: